Efficacy and safety assessment of Centella asiatica as an herbal dietary supplement to reduce blood sugar levels in type II diabetes patients in Thailand.

Status

Unknown

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230928003

Enrollment

Registered

2023-09-28

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II diabetes Type II diabetes

Interventions

The extraction of Centella asiatica in capsule,Placebo capsule

Active Comparator Dietary Supplement,Placebo Comparator Dietary Supplement

Centella asiatica,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Type II Diabetes patient 2. Age 18-65 years old

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Type I diabetes 3. HbA1c level >= 10 4. On insulin treatment 5. Hypothyroidism or hyperthyroidism 6. Severe liver dysfunction within 6 months : alanin aminotransferase (ALT) or aspartate amionotransferase (AST) > 5 times of normal limit, INR > 6.5, Bilirubin > 17.5 mg/dL 7. Creatinine > 3.5 mg/dL or eGFR < 30 ml/min/1.73 m2 within 6 months 8. Severe allergy to Centella asiatica

Design outcomes

Primary

Measure	Time frame
Efficacy 6 months Blood sugar level	—

Secondary

Measure	Time frame
Safety 6 months Adverse events	—

Countries

Thailand

Contacts

Public ContactDoungkamol Siriarchawawat

Walailak University

doungkamol.si@wu.ac.th075477484

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026